GlaxoSmithKline's Nucala targets rival AstraZeneca with FDA nod for rare white blood cell disease

GlaxoSmithKline's Nucala targets rival AstraZeneca with FDA nod for rare white blood cell disease

Source: 
Fierce Pharma
snippet: 

The FDA gave GSK's Nucala the green light to treat hypereosinophilic syndrome (HES), making it the first biologic approved for the disease, the British drugmaker said Friday.